FDAClass II · Drug · Recalled June 10, 2026

EQUALINE ultra strength recall — Guardian Drug Co. Inc.

Hazard: Presence of foreign substance: small metallic particles in chewable tablets.

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID: D-0577-2026
Brand: Guardian Drug Co
Classification: Class II
Recall status: Ongoing
Initiated: Voluntary: Firm initiated

Description

EQUALINE ultra strength, antacid tablets, calcium carbonate 1000mg, 72 chewable tablets, DISTRIBUTED BY SUPERVALU INC.,EDEN PRARIE, MN 55344 USA, NDC 41163-171-68.

Affected products

EQUALINE ultra strength

Companies & origin

Recalling firm location: Dayton, NJ, United States
Firm address: 2 Charles Ct, 08810-1508

Identifying details (verbatim from the notice)

Product codes / lots: Lot #: 1716089, expires: JAN- 2029.
Distribution: U.S.A. Nationwide
Firm notified the public via: Letter
FDA event ID: 99098
Recall initiated: May 28, 2026
FDA classified: June 3, 2026
FDA report date: June 10, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 24, 2026 at 12:00 AM UTC.

Report a data error on this page